In the current retrospective cohort study, conducted by both pain specialists and neurophysiologists, the primary outcome was to search for the effect of obesity on the efficacy of PRF of LFCN in refractory MP for 6 months. Secondary outcomes were to identify the clinical and diagnostic features of the MP.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* older than 18 years treated with PRF neuromodulation of LFCN for MP
* followed up at least 6 months in the pain clinic of the tertiary hospital between January 2020 and August 2023.
Exclusion Criteria:
* inadequate follow-up or missing documentation
* If a new analgesic drug was prescribed during the follow-up period that could affect the evaluation of outcomes, the patients were also excluded.
* Patients who missed appointments, or were unable to communicate with; were not included in the study.
* Patients with secondary entrapment neuropathy (e.g., diabetes, inflammatory arthritis, hypothyroidism), malignancy, pregnancy, skin infection in the inguinal region or dermatitis, lumbar radiculopathy, polyneuropathy, and cardiac pacemakers were excluded.
* In the SSEP analysis, when the latency of LFCN was not evaluated in both sides, these patients were not also included in the study.